Literature DB >> 2039206

In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins.

H Saito1, H Tomioka, K Sato, M Emori, T Yamane, K Yamashita, K Hosoe, T Hidaka.   

Abstract

Newly synthesized rifamycin derivatives, KRM-1648, KRM-1657, KRM-1668, KRM-1686, and KRM-1687, having the chemical structures of 3'-hydroxy-5'-(4-alkylpiperazinyl)-benzoxazinorifamycins (alkyl residues: isobutyl, propyl, sec-butyl, sec-butyl [R configuration], and sec-butyl [S configuration], respectively), were studied for their in vitro antimycobacterial activities. Representative (KRM-1648) MICs for 90% of the strains tested, determined by the agar dilution method on 7H11 medium, of various pathogenic mycobacteria (9 species, 174 strains) were as follows (in micrograms per milliliter): Mycobacterium tuberculosis (rifampin [RMP]-susceptible strains), less than or equal to 0.0125; M. tuberculosis (RMP-resistant strains), 12.5; M. kansasii, 0.05; M. marinum, less than or equal to 0.0125; M. scrofulaceum, 0.1; M. avium, 1.56; M. intracellulare, 0.1; M. fortuitum, greater than 100; and M. chelonae subsp. abscessus and M. chelonae subsp. chelonae, greater than 100. These values are more than 64 times lower than those of RMP, except for the values against RMP-resistant M. tuberculosis (8 times lower) and those against rapid growers, including M. fortuitum and M. chelonae (the same as those of RMP). The other derivatives had similar levels of in vitro activity against these mycobacteria. When murine peritoneal macrophages in which M. intracellulare was phagocytosed in vitro were cultured in the presence of the benzoxazinorifamycins (1 microgram/ml), much more rapid killing of the organisms ingested in the macrophages was seen compared with when the same amount of RMP was added to the medium. The addition of benzoxazinorifamycins at the concentration of 0.05 micrograms/ml caused more marked suppression of intracellular growth of the organisms compared with addition of RMP. KRM-1648 and KRM-1657 inhibited intracellular growth of M. tuberculosis, and their efficacies were much greater than that of RMP.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2039206      PMCID: PMC245047          DOI: 10.1128/AAC.35.3.542

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  Response to chemotherapy of pulmonary infection due to Mycobacterium kansasii.

Authors:  G D Harris; W G Johanson; D P Nicholson
Journal:  Am Rev Respir Dis       Date:  1975-07

2.  Permeability barrier to rifampin in mycobacteria.

Authors:  J Hui; N Gordon; R Kajioka
Journal:  Antimicrob Agents Chemother       Date:  1977-05       Impact factor: 5.191

Review 3.  Nontuberculous mycobacteria and associated diseases.

Authors:  E Wolinsky
Journal:  Am Rev Respir Dis       Date:  1979-01

4.  Mode of action of rafamycin on the RNA polymerase reaction.

Authors:  A Sippel; G Hartmann
Journal:  Biochim Biophys Acta       Date:  1968-03-18

5.  Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin.

Authors:  W Pezzia; J W Raleigh; M C Bailey; E A Toth; J Silverblatt
Journal:  Rev Infect Dis       Date:  1981 Sep-Oct

6.  In vitro activities against mycobacteria of two long-acting rifamycins, FCE22807 and CGP40/469A (SPA-S-565).

Authors:  J M Dickinson; D A Mitchison
Journal:  Tubercle       Date:  1990-06

7.  Treatment of disease due to Mycobacterium intracellulare.

Authors:  P T Davidson; V Khanijo; M Goble; T S Moulding
Journal:  Rev Infect Dis       Date:  1981 Sep-Oct

8.  In vitro susceptibility of Mycobacterium avium complex and Mycobacterium tuberculosis strains to a spiro-piperidyl rifamycin.

Authors:  C L Woodley; J O Kilburn
Journal:  Am Rev Respir Dis       Date:  1982-09

9.  Multiple drug resistance in Mycobacterium avium: is the wall architecture responsible for exclusion of antimicrobial agents?

Authors:  N Rastogi; C Frehel; A Ryter; H Ohayon; M Lesourd; H L David
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

10.  Antibacterial activity of DL 473, a new semisynthetic rifamycin derivative.

Authors:  V Arioli; M Berti; G Carniti; E Randisi; E Rossi; R Scotti
Journal:  J Antibiot (Tokyo)       Date:  1981-08       Impact factor: 2.649

View more
  24 in total

1.  In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657.

Authors:  J K Akada; M Shirai; K Fujii; K Okita; T Nakazawa
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Therapeutic efficacy of the benzoxazinorifamycin KRM-1648 against experimental Mycobacterium avium infection induced in rabbits.

Authors:  M Emori; H Saito; K Sato; H Tomioka; T Setogawa; T Hidaka
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

3.  In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a.

Authors:  H Saito; H Tomioka; K Sato; S Dekio
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

4.  Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin.

Authors:  H Tomioka; H Saito; K Sato
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

5.  Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model.

Authors:  S P Klemens; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

6.  Luciferase in vivo expression technology: use of recombinant mycobacterial reporter strains to evaluate antimycobacterial activity in mice.

Authors:  M J Hickey; T M Arain; R M Shawar; D J Humble; M H Langhorne; J N Morgenroth; C K Stover
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

7.  Activity of KRM-1648 alone or in combination with both ethambutol and kanamycin or clarithromycin against Mycobacterium intracellulare infections in beige mice.

Authors:  T Yamamoto; R Amitani; K Suzuki; E Tanaka; T Murayama; F Kuze
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

8.  In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis.

Authors:  T Yamamoto; R Amitani; K Suzuki; E Tanaka; T Murayama; F Kuze
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

9.  Anticytomegaloviral activity of methotrexate associated with preferential accumulation of drug by cytomegalovirus-infected cells.

Authors:  M Wachsman; F M Hamzeh; H Saito; P S Lietman
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

10.  How effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice?

Authors:  B Ji; N Lounis; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.